Pub Date : 2019-07-01DOI: 10.1142/S2661341719720015
R. Chu, P. Wong, J. K. M. Wai, F. Yap
Granulomatosis with Polyangiitis (GPA) is a form of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. We report a case of a 56-year-old man with GPA who first presented with acute urinary retention, and then developed pulmonarycavitating lesions and subarachnoid hemorrhage (SAH). The SAH was due to a ruptured right vertebral artery aneurysm, whichwas subsequently embolized. The patient initially had a good response to immunosuppressive therapy but later succumbed due to fulminant sepsis. SAH is a rare complication of GPA and usually not associated with a detectable aneurysm. Our patient is thesecond case in the literature where an aneurysm had been detected on angiography and the first case where examination of the culprit aneurysm revealed features of vasculitis.
{"title":"Subarachnoid Hemorrhage and Prostatic Involvement in Granulomatosis with Polyangiitis – An Atypical Presentation","authors":"R. Chu, P. Wong, J. K. M. Wai, F. Yap","doi":"10.1142/S2661341719720015","DOIUrl":"https://doi.org/10.1142/S2661341719720015","url":null,"abstract":"Granulomatosis with Polyangiitis (GPA) is a form of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. We report a case of a 56-year-old man with GPA who first presented with acute urinary retention, and then developed pulmonarycavitating lesions and subarachnoid hemorrhage (SAH). The SAH was due to a ruptured right vertebral artery aneurysm, whichwas subsequently embolized. The patient initially had a good response to immunosuppressive therapy but later succumbed due to fulminant sepsis. SAH is a rare complication of GPA and usually not associated with a detectable aneurysm. Our patient is thesecond case in the literature where an aneurysm had been detected on angiography and the first case where examination of the culprit aneurysm revealed features of vasculitis.","PeriodicalId":15538,"journal":{"name":"Journal of Clinical Rheumatology and Immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1142/S2661341719720015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49089656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-01DOI: 10.1142/S2661341719500020
Tsz-Yuen wu, K. Ying
Rheumatic diseases occur commonly in patients of childbearing age. The compatibility of different Disease Modifying Anti-Rheumatic Drugs (DMARDs) during pregnancy and lactation can affect the management decision when treating these patients. With the development of promising biologics DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) in various rheumatic diseases, their safety in pregnancy and lactation is an issue for both patients and clinicians. Recently, three different guidelines on the compatibility of DMARDs during pregnancy and lactation has been published by ACR, EULAR and BSR respectively. This article summarizes their recommendations on the management of patients on DMARDs during pregnancy and lactation.
{"title":"Disease Modifying Anti-Rheumatic Drugs: Review on Pregnancy and Lactation","authors":"Tsz-Yuen wu, K. Ying","doi":"10.1142/S2661341719500020","DOIUrl":"https://doi.org/10.1142/S2661341719500020","url":null,"abstract":"Rheumatic diseases occur commonly in patients of childbearing age. The compatibility of different Disease Modifying Anti-Rheumatic Drugs (DMARDs) during pregnancy and lactation can affect the management decision when treating these patients. With the development of promising biologics DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) in various rheumatic diseases, their safety in pregnancy and lactation is an issue for both patients and clinicians. Recently, three different guidelines on the compatibility of DMARDs during pregnancy and lactation has been published by ACR, EULAR and BSR respectively. This article summarizes their recommendations on the management of patients on DMARDs during pregnancy and lactation.","PeriodicalId":15538,"journal":{"name":"Journal of Clinical Rheumatology and Immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1142/S2661341719500020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45942575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：